Navigation Links
Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
Date:9/14/2007

PITTSBURGH, Sept. 14 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced the appointment of M. Fabiana Lacerca to the position of Senior Vice President and Chief Compliance Officer.

Ms. Lacerca joins Mylan from Bristol-Meyers Squibb where she was Director of Compliance for Latin America, Canada and Puerto Rico. While there, she was responsible for all compliance-related matters in those regions. Prior to Bristol-Meyers Squibb, Ms. Lacerca held executive and senior counsel positions with Merck & Co., Microsoft and AT&T.

Ms. Lacerca has extensive experience in the areas of multi-jurisdictional corporate compliance, international business transactions, pharmaceutical industry regulation, corporate policy and international environmental law and has advised on opportunities and legal trends within the government as well as corporate sectors.

Mylan Vice Chairman and CEO Robert J. Coury commented: "As we transition to becoming a global leader in our industry we are committed to maintaining a culture of integrity and quality across all lines of our business. It is with great pleasure, therefore, to welcome Fabiana to Mylan. Fabiana has tremendous experience and an exemplary track record in international corporate compliance, which she has gained advising a number of Fortune 100 companies on a wide range of issues, including corporate policy and cross border transactions. Fabiana's extensive experience counseling companies in the pharmaceutical industry with operations in multiple countries will be invaluable to Mylan's operations around the world."

Ms. Lacerca earned a master's of law (LL.M) from UCLA; a specialization in international environmental law from the Universidad de Buenos Aires; and a bachelor's of law from the Universidad de Buenos Aires.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... planning services and products in the developing world, is pleased to release their ... prevent over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Clearinghouse supporting the real time adjudication of medical service claims by Pharmacy Benefit ... their current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard ...
(Date:5/25/2016)... ... , ... The University of San Francisco (USF) has named Margaret Wooding Baker ... of more than 100 full-time faculty and staff, and serve as a member of ... , Baker comes to USF from the University of Washington in Seattle, where she ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center ... hands of time of female aging. The Juliet™ procedure helps to ... such as leakage, laxity, itchiness and pain have reported real relief from these and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State ... Meeting for their work on visual evoked potential and human attention. The article, ... used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: